Cross-Border Impact Ventures
Impact investorToronto · Series A–Series B · 12 people tracked
Investment thesis
The firm invests in companies commercializing globally relevant medical devices, diagnostics, therapeutics and digital health innovations that address market opportunities in women, children and adolescent health. It focuses on four areas: sexual and reproductive health; maternal, newborn and child health; general health including chronic diseases; and health software infrastructure. Applying a gender and diversity lens, it targets companies addressing gender health inequalities and pursues both positive impact and financial returns. As hands-on investors, the firm supports management teams with access to new markets, unique forms of capital and health technology expertise across North America, Europe and global markets.
Source: firm website, verified Aug 25, 2026.
Team · 12 people
from the firm's website & curated & public directories
What they invest in
from 8 of 11 portfolio companiesMedical Devices ×6Digital Health ×5Healthtech ×5AI & Machine Learning ×4FemTech ×3Biotech ×1Hardware ×1SaaS ×1
HQs:United States×3United Kingdom×2
Investments · 11 tracked
founders shown can be your intro pathBy year:2025 · 12022 · 12 dated
Oxford Cancer Analytics develops a diagnostics platform that combines reproducible proteomic measurement with AI to produce evidence-based insights supporting clinical decision-making.
AI & Machine LearningBiotechMedical DevicesOxford, GB
Andreas Halner(Founder and Head of Healthcare AI)inHeinrich Roder(Chief Technology Officer)inDaniel Szulc(Chief Product Officer)in
Co-investorsEka VenturesMeridian Health VenturesUK Innovation & Science Seed FundCivilization Ventures Management, LlcDigitalDx VenturesOnstage+1 more
Axena Health develops the Leva Pelvic Health System, a clinically tested, non-invasive treatment for pelvic health conditions such as incontinence.
Digital HealthFemTechHealthtechMedical DevicesAuburndale, US
Samantha Pulliam(Executive Officer, Director)Vincent Ricci(Executive Officer)Jim O'Connor(Executive Officer)Shacey Petrovic(Executive Officer, Director)Eileen Maus(Executive Officer, Director)
BoardJonathan Dean(Director)
Co-investorsCatalio Capital Management, LPAvestria Ventures
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit K. Gupta(Executive Officer, Director)Omer Inan(Co-founder, Chief Scientific Officer)Andrew Carek(Co-founder, Chief Technical Officer)Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan, PhD(Co-founder, Chief Scientific Officer)in
Co-investorsBayMed Venture PartnersBroadview VenturesLaerdal Million Lives FundOSF VenturesPortal InnovationsHatteras Venture Partners
Femtech gynecological health platform offering period care products, a pelvic pain clinic, and tampon-based diagnostic testing.
Co-investorsGuinness VenturesJazzya InvestmentsMyelin VCSimplyhealth Ventures
mOm develops the mOm Essential, a neonatal incubator that warms newborns to normal body temperature to prevent hypothermia and avoidable NICU admissions.
HardwareHealthtechMedical DevicesEdinburgh, GB
James Roberts(CEO, Co-Founder & Board)Richard Marlow(CFO (Board))Daniel Green(Chief Operating Officer)
Co-investorsCambridge Angels groupConduit Connect
OncoLens provides a platform that connects cancer care teams and enables multidisciplinary cancer management, helping cancer centers coordinate care, manage tumor boards, and access clinical trials and biomarker testing.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSaaS
Anju Mathew(Co-Founder and CEO)Lijo Simpson(Chief Medical Officer)
Co-investorsAtlanta Technology AngelsBIP VenturesMartin VenturesSeedToBBIP Capital
Biomarker discovery platform (OXcan) using proteomics and machine learning for affordable liquid-biopsy cancer detection.
Co-investorsEka Ventures
Pendulum is a probiotic and prebiotic supplement company that develops clinically-tested products targeting gut health, metabolic function, and glucose control, including proprietary strains like live Akkermansia.
HealthtechWellness & Fitness
Co-investorsDCVC (Data Collective)Felicis VenturesLowercarbon CapitalSequoia CapitalTrue VenturesDecisive Point+1 more
Health infrastructure software using AI/ML to forecast healthcare demand and reduce supply chain wastage and stockouts.
Raydiant Oximetry is a clinical-stage medical device company developing Lumerah, a noninvasive fetal pulse oximeter that directly measures fetal oxygen levels using biophotonics and machine learning.
Digital HealthFemTechMedical DevicesSan Ramon, US
Neil P. Ray(Executive Officer, Director)Michael Nagel(Chief Executive Officer)
BoardCharles McDonald(Director)John Maroney(Director)
Co-investorsBand of AngelsFemHealth VenturesSteelSky VenturesTri-Valley VenturesAvestria VenturesBill & Melinda Gates Foundation+3 more
Sonio is a cloud-native, AI-powered platform that standardizes and automates fetal ultrasound workflows, covering image acquisition, reporting, quality review, and billing handoff.
AI & Machine LearningDigital HealthFemTech
Cecile Brosset Dubois(Founder)in
Co-investorsElaiaOneRagtimeSTATION FBpifrance
Portfolio news
latest coverage across their companiesFrequently asked questions
- How many investments has Cross-Border Impact Ventures made?
- Cross-Border Impact Ventures has 9 tracked investments.
- What stage does Cross-Border Impact Ventures invest at?
- Cross-Border Impact Ventures invests at the Series A, Series B stages.
- What is Cross-Border Impact Ventures's typical check size?
- Cross-Border Impact Ventures typically writes checks of $2M – $10M.
- What sectors does Cross-Border Impact Ventures focus on?
- Cross-Border Impact Ventures focuses on AI & Machine Learning, Biotech, Digital Health, FemTech, Healthtech, Impact & Social Good, Medical Devices, SaaS.
- Where is Cross-Border Impact Ventures located?
- Cross-Border Impact Ventures is headquartered in Toronto, CA.
- Who does Cross-Border Impact Ventures co-invest with?
- Cross-Border Impact Ventures most often shares deals with BayMed Venture Partners, FemHealth Ventures, Foreground Capital, among 24 tracked co-investors.
Similar investors
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Foreground Capital is a venture capital firm dedicated to investing in the future of women's health, building on its predecessor track record at RH Capital.
Portfolia operates venture funds designed by and for women, enabling members to invest collectively in innovative companies while learning together through curated content, founder access, and hands-on deal flow.
WELL Health Ventures is the corporate venture arm of WELL Health Technologies, backing digital health companies with an emphasis on modernizing healthcare in Canada.